Amniotic cell therapy - NuCel

Drug Profile

Amniotic cell therapy - NuCel

Alternative Names: Human amniotic allograft; NuCel; ReNu™

Latest Information Update: 10 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuCel
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders
  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 21 Feb 2014 OhioHealth & NuCel initiate enrolment in a phase II trial for Intervertebral disc degeneration in USA (NCT02070484)
  • 27 Dec 2013 Phase-II clinical trials in Intervertebral disc degeneration in USA (Intralumbar)
  • 01 Jan 2009 Launched for Bone disorders in USA (Perilesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top